| Released | Contributor | Author | Title | Pages | Price |
|---|
| May 20, 2013 | Alpha Street Research | Hunter Orr | VRX - Valeant Pharmaceuticals International Inc - Rated a Hold - Company Analysis and ASR Ranking Report | 9 | $24 | | May 19, 2013 | Market Edge | N/A | Market Edge Equity Research Report | 4 | $10 | | May 17, 2013 | Reuters Investment Profile | N/A | Valeant Pharmaceuticals International Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. | 12 | $138 | | May 16, 2013 | Thomson Reuters Stock Report | StockReports + Research Department | Thomson Reuters Stock Report - VALEANT PHARMACEUTICALS INTERNATIONAL INC (VRX-N) | 12 | $25 | | May 16, 2013 | New Constructs, LLC | N/A | VRX: Due Diligence Review: Forensic Earnings and Valuation | 13 | $25 | | May 16, 2013 | Stock Traders Daily | Thomas H Kee Jr. | Trading Report for (VRX). A detailed report, including free correlated market analysis, and updates. | 5 | $57.50 | | May 16, 2013 | ValuEngine, Inc. | N/A | ValuEngine Industry Report for Medical-drugs | 18 | $207 | | May 16, 2013 | S&P Capital IQ – STARS Reports | N/A | Valeant Pharmaceuticals Intl | 9 | $103.50 | | May 15, 2013 | ValuEngine, Inc. | N/A | ValuEngine - Toronto Quantitative Stock Report for VRX | 11 | $126.50 | | May 15, 2013 | ValuEngine, Inc. | N/A | ValuEngine Detailed Valuation Report for VRX | 11 | $126.50 |
|
View All Reports for VRX ... |
|
|
2.42(3.19%) May 17, 4:05PM EDT